These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21539876)

  • 21. PSA-based vaccines for the treatment of prostate cancer.
    Madan RA; Gulley JL; Arlen PM
    Expert Rev Vaccines; 2006 Apr; 5(2):199-209. PubMed ID: 16608420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
    Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
    Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer.
    Bradford TJ; Wang X; Chinnaiyan AM
    Urol Oncol; 2006; 24(3):237-42. PubMed ID: 16678056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP.
    Young CY; Montgomery BT; Andrews PE; Qui SD; Bilhartz DL; Tindall DJ
    Cancer Res; 1991 Jul; 51(14):3748-52. PubMed ID: 1712248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
    Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY
    J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
    Harada M; Kobayashi K; Matsueda S; Nakagawa M; Noguchi M; Itoh K
    Prostate; 2003 Oct; 57(2):152-9. PubMed ID: 12949939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of BoHV-1 gE envelope glycoprotein mimotopes obtained by phage display.
    Lehmann D; Sodoyer R; Leterme S
    Vet Microbiol; 2004 Nov; 104(1-2):1-17. PubMed ID: 15530735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
    Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
    Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A.
    Wu HC; Yeh CT; Huang YL; Tarn LJ; Lung CC
    Appl Environ Microbiol; 2001 Jul; 67(7):3201-7. PubMed ID: 11425742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation.
    Uhlin M; Okas M; Karlsson H; Gertow J; Henningsohn L; Ringdén O; Kärre K; Levitsky V; Mattsson J
    Transplantation; 2009 Feb; 87(4):467-72. PubMed ID: 19307781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics.
    Phalipon A; Folgori A; Arondel J; Sgaramella G; Fortugno P; Cortese R; Sansonetti PJ; Felici F
    Eur J Immunol; 1997 Oct; 27(10):2620-5. PubMed ID: 9368618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.
    Klyushnenkova EN; Kouiavskaia DV; Kodak JA; Vandenbark AA; Alexander RB
    Prostate; 2007 Jul; 67(10):1019-28. PubMed ID: 17455230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guided selection of an anti-gamma-seminoprotein human Fab for antibody directed enzyme prodrug therapy of prostate cancer.
    Zhang Q; Zhang SH; Su MQ; Bao GQ; Liu JY; Yi J; Shen JJ; Hao XK
    Cancer Immunol Immunother; 2007 Apr; 56(4):477-89. PubMed ID: 16868778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses.
    Kieber-Emmons T; Luo P; Qiu J; Chang TY; O I; Blaszczyk-Thurin M; Steplewski Z
    Nat Biotechnol; 1999 Jul; 17(7):660-5. PubMed ID: 10404158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and characterization of Ch806 mimotopes.
    Yang L; Jiang H; Shi B; Wang H; Li J; Wang H; Yao M; Li Z
    Cancer Immunol Immunother; 2010 Oct; 59(10):1481-7. PubMed ID: 20544195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display.
    Fosså A; Alsøe L; Crameri R; Funderud S; Gaudernack G; Smeland EB
    Cancer Immunol Immunother; 2004 May; 53(5):431-8. PubMed ID: 14747957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection of peptidic mimics of digoxin from phage-displayed peptide libraries by anti-digoxin antibodies.
    Ball WJ; Wang Z; Malik B; Kasturi R; Dey P; Short MK; Margolies MN
    J Mol Biol; 2000 Aug; 301(1):101-15. PubMed ID: 10926495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular recognition of a peptide mimic of the Lewis Y antigen by an anti-Lewis Y antibody.
    Murali R; Kieber-Emmons T
    J Mol Recognit; 1997; 10(6):269-76. PubMed ID: 9770651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer.
    Perambakam S; Xue BH; Sosman JA; Peace DJ
    Cancer Immunol Immunother; 2002 Jul; 51(5):263-70. PubMed ID: 12070713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.